Summary In mammalian cells, there are two isoforms of DNA topoisomerase 11, designated a (170-kDa form) and ,B (180-kDa form). Previous studies using cell lines have shown that the topoisomerase Ila and [ isoforms are differentially regulated during the cell cycle and in response to changes in growth state. Moreover, both isoforms can act as targets for a range of anti-tumour drugs. Here, we have analysed the normal tissue distribution in humans of topoisomerase Ila and f using isoform-specific antibodies. In addition, we have studied expression of these isoforms in 69 primary tumour biopsies, representative either of tumours that are responsive to topoisomerase 11-targeting drugs (breast, lung, lymphoma and seminoma) or of those that show de novo drug resistance (colon). Topoisomerase lla was expressed exclusively in the proliferating compartments of all normal tissues, and was detectable in both the cell nucleus and cytoplasm. In biologically aggressive or rapidly proliferating tumours (e.g. high-grade lymphomas and seminomas), there was a high level of topoisomerase Ila, although expression was still detectable in colon tumours, indicating that expression of this isoform is not sufficient to explain the intrinsic drug resistance of colon tumours. Topoisomerase Ill was expressed ubiquitously in vivo and was localized in both the nucleoli and the nucleoplasm. This isoform was present in quiescent cell populations, but was expressed at a generally higher level in all tumours and proliferating cells than in normal quiescent tissues. We conclude that topoisomerase Ila is a strict proliferation marker in normal and neoplastic cells in vivo, but that topoisomerase ll[ has a much more general cell and tissue distribution than has topoisomerase Ila. The apparent up-regulation of topoisomerase II,B in neoplastic cells has implications for the response of patients to anti-tumour therapies that include topoisomerase Il-targeting drugs.
Topoisomerase II is a homodimeric nuclear protein with many different roles in DNA metabolism, including relief of torsional stress and mitotic chromosome condensation and segregation (reviewed in Wang, 1985 in Wang, , 1991 Watt and Hickson, 1994) . Topoisomerase II is also one of the most important determinants of cellular sensitivity to a range of clinically important anti-tumour drugs. For example, topoisomerase II is the primary cellular target for several intercalating agents, including doxorubicin, mitoxantrone and epirubicin, as well as for the non-intercalating epipodophyllotoxins, etoposide and teniposide (reviewed in Osheroff et al, 1991; Pommier, 1993; Beck et al, 1993) . Topoisomerase II is a so-called type II enzyme, defined as acting via the creation of double-stranded breaks in DNA, through which an intact DNA duplex is passed, before the break is resealed. As part of this breakage and religation process, a transient reaction intermediate is generated, termed the cleavage complex, consisting of a topoisomerase II dimer bound covalently to the 5' phosphoryl groups of the cleaved DNA (Osheroff et al, 1991) . It is at the cleavable complex stage that topoisomerase II-targeting drugs have their primary effect, as a result of inhibiting DNA strand break religation. As a consequence, cells treated with topoisomerase II inhibitors accumulate DNA strand breaks bound covalently by topoisomerase II protein. These breaks lead ultimately to cell death via an apoptotic pathway, although the details of the downstream signalling from cleavable complexes to cell death are poorly understood.
Cellular responses to topoisomerase II-targeting drugs depend, at least in part, on the expression level of the target enzyme. High topoisomerase II protein levels confer relative drug sensitivity (Davies et al, 1988; Fry et al, 1991) , while low levels confer resistance (reviewed in Pommier, 1993; Beck et al, 1993) . Although topoisomerase II is well established as a key nuclear target for cytotoxic drugs, it is not clear which of the two known isoforms (Tsai-Pflugfelder et al, 1988; Tan et al, 1992; Jenkins et al, 1992; Austin et al, 1993) (Woessner et al, 1991; Prosperi et al, 1994; Isaacs et al, 1996) . In contrast, topoisomerase Ilp is expressed in cycling and non-cycling cell lines (Woessner et al, 1991) .
Although topoisomerase II[ does not appear to be regulated Topoisomerase Ila and P in cancer 1341 during the transition from proliferation to quiescence in vitro, data derived from studies on human lymphocytes indicate that topoisomerase II[ may be regulated in vivo by the proliferation status of cells (Kaufmann et al, 1994) . The ability of topoisomerase IItargeting drugs to kill cell lines in vitro is also strongly dependent upon cell proliferation, with quiescent cells showing an enhanced level of drug resistance (Osheroff et al, 1991; Pommier, 1993; Beck et al, 1993) . It is important to know, therefore, whether the topoisomerase Ila and [ isoforms are differentially expressed and/or regulated in vivo. Here, we have studied the normal tissue distribution in humans of the topoisomerase Ila and [B proteins using isoform-specific monoclonal antibodies. In addition, we have analysed representative samples of malignant cells from tumour types in which topoisomerase II inhibitors are routinely used therapeutically. We show that, although topoisomerase IIa is a strict proliferation marker in vivo, topoisomerase 11, is expressed widely and in all tissue types, including within quiescent cell compartments. In contrast to some previous reports, we find that topoisomerase II is detectable both in the nucleoplasm and in nucleoli, and is expressed at a generally higher level in neoplastic than in normal tissues.
MATERIALS AND METHODS Growth and immunocytochemical analysis of cell lines
Cell lines were grown in RPMI-1640 medium (Gibco-BRL) supplemented with 10% fetal bovine serum, 4 mm glutamine and antibiotics in a humidified atmosphere containing 5% carbon dioxide at 370C. For immunocytochemical staining, cytospin samples were prepared on glass slides using a Shandon cytocentrifuge. The cytospin samples were then air dried and fixed in phosphate-buffered saline (PBS) containing 3.7% formalin for 15 min before immunostaining. The cell lines used were as follows: SUDHL-1 (T-cell lymphoma), (breast carcinoma), SuSa (testicular teratoma), NC1460 (non-small-cell lung cancer) and CEM (erythroleukaemia). 
Antibodies
The CRB antibody was raised in rabbits to an extreme C-terminal peptide of the human topoisomerase IlIa protein (Arg-Ala-Lys-LysPro-Ile-Lys-Tyr-Leu -Glu-Glu-Ser-Asp-Glu-Asp-Asp-Leu-Phe) and was supplied by Cambridge Research Biochemicals (UK). This antibody has been validated in previous studies (Smith and Makinson, 1989; Wells et al, 1994) . The generation of the 3H10 antibody specific for topoisomerase 11, will be described in detail elsewhere (N Nozaki et al, manuscript in preparation). Briefly, a peptide encompassing residues 1583-1601 (SDFPTEPPSLPRT-GRARKE) of the deduced human topoisomerase IlI sequence (Jenkins et al, 1992) was synthesized, conjugated to keyhole limpet haemocyanin, and was injected four times every 2 weeks into a Balb/c mouse. Antibody-secreting cells were screened using a partially purified preparation of topoisomerase II from HL60 cells. The hybridoma 3H10 was cloned and shown to secrete antibody of the IgG2a subtype.
Western blotting
Whole-cell extracts from the human lung carcinoma cell line NCI460 and an etoposide-resistant derivative, designated NC1460/pV8, were prepared for Western blotting by lysing cells directly in sodium dodecyl sulphate (SDS) sample buffer (200 jg protein ml-') before separation on a 7% SDS-polyacrylamide gel (Laemmli, 1970 Figure 1 The CRB and 3H10 antisera detect 170-kDa and 180-kDa proteins, respectively, in human cell nuclear extracts. A 0.35 M sodium chloride nuclear protein extract prepared from NC1460 cells (lanes 2 and 4) or NC1460/pV8 cells (lanes 1 and 3) was electrophoresed alongside molecular weight standards on a 9% SDS-polyacrylamide gel, transferred to Hybond-N, and the membrane was exposed either to the CRB antiserum (lanes 1 and 2) or to a mixture of the CRB and 3H10 antisera (lanes 3 and 4). Antibody detection was the ECL system. Molecular weights (in kDa) are indicated on the left. The positions of the 170-kDa topoisomerase lla and the 180-kDa topoisomerase lip protein are indicated on the right RESULTS Characterization of topoisomerase 11 isoform-specific antibodies Western blotting with the CRB antibody raised to a synthetic peptide from the topoisomerase IIh protein sequence (that is not conserved in topoisomerase II) revealed a single 1 70-kDa immunoreactive protein consistent with the known size of the topoisomerase Ila protein (Figure 1 ). This antibody has been shown in previous studies to be specific for the topoisomerase lloz isoform (Smith and Makinson, 1989; Wells et al, 1994) . When the CRB and the 3H10 (which was raised to a non-conserved peptide from the topoisomerase IlI sequence) antibodies were mixed and the same filter was exposed simultaneously to both antibodies, a second 180-kDa immunoreactive protein of the size of topoisomerase Ilf was revealed (Figure 1 ). Western blots using the 3H10 antibody alone revealed a single immunoreactive protein of 180 kDa, which co-migrated with topoisomerase IIp protein detected with a previously characterized (Houlbrook et al, 1995) rabbit polyclonal anti-topoisomerase II3 antiserum raised against recombinant protein (data not shown). Thus, we conclude that the CRB and 3H10 antibodies are specific for the oc and D isoforms of topoisomerase II respectively.
Normal tissue distribution of topoisomerase 1I1a and D in humans Topoisomerase Ila
The anti-topoisomerase Ia peptide antiserum, CRB, produced nuclear staining in all of the normal tissues studied with a distribution very similar to that seen with known proliferation-associated antigens, such as Ki-67 (Figure 2 ). For example, in lymphoid tissue, topoisomerase II-expressing cells were numerous in the germinal centres, but scarce in mantle zones. In epithelium and testicular tubules, positive staining for topoisomerase IIa was present in the basal layers, but not in the more mature superficial cells. In colon and lung, positive staining was present in a minority of basal and alveolar epithelial cells respectively. In other tissues, including liver, kidney and brain in which the majority of the cells are mature and non-proliferating, positive staining was limited to a few scattered cells. Cytoplasmic staining was noted in some tissues, and was found in the same cell populations in which nuclear staining was evident.
Topoisomerase 11p
The anti-topoisomerase Ilf peptide 3H 10 antiserum produced positive staining in virtually all cell nuclei within all of the normal tissues studied (Figure 2) . A punctate pattern of nuclear staining was evident, which was localized both within nucleoli and dispersed throughout the nucleoplasm. In areas representing proliferating cell populations, such as lymphoid germinal centres, the nucleoli appeared larger, and there was a greater dispersion of immunoreactive material into the surrounding nucleoplasm. In colon there were scattered nuclear dots in most of the cells.
Expression of topoisomerase lhex and D in neoplastic tissues Topoisomerase Ila The staining pattern for topoisomerase IIo protein seen in the range of tumours examined reflected that of the normal tissues described above. The CRB antibody gave a pattern of nuclear staining that strongly correlated with that seen with antibodies to the established proliferation marker, Ki-67 antigen. Of particular note was the striking positivity of the abnormal mono-and multinucleate cells in cases of Hodgkin's disease (Figure 2 ). Cytoplasmic staining with the CRB antibody was noted and was generally more evident in the tumour biopsies than it was in the normal tissue samples.
The proportion of tumour cells staining positive for topoisomerase 11o ranged from less than 5% to more than 60%, and this was related to tumour type and grade ( Figure 2 and analysed. No direct association with proliferative index (and therefore with topoisomerase Ila expression) was evident, although there was a generally higher intensity of staining in tumour tissue than that seen in normal tissues (Figure 2) . In each tumour sample, a minimum of 50% of the cells stained positive for topoisomerase 11, although in most cases more than 90% of cells expressed topoisomerase II. As with normal tissues, staining within both nucleoli and in the nucleoplasm was evident with the 3H10 antibody, but more intense staining coincided with nucleolar structures. In lymphoid neoplasms, only a limited amount of cytoplasmic staining was evident, but in the seminomas and epithelial neoplasms (lung colon and breast cancer), many cells had a low level of detectable cytoplasmic staining.
Expression of topoisomerase lla and 1B in cell lines
Topoisomerase Ila Staining of cell lines with the CRB antibody showed nuclear staining with nucleolar accentuation. The mitotic figures were strongly positive (Figure 3 ). There was some cytoplasmic staining, but this was weak.
Topoisomerase Il,B Staining with 3H10 on all of the lines showed a different pattern from that of CRB. The pattern was nuclear, but showed a granular distribution (Figure 3 ). :.
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Topoisomerase lla and, in cancer 1345 in the germinal centres of tonsil tissue, consistent with a proliferation-specific pattern of expression (Woessner et al, 1991) and in agreement with our data using a different antibody to topoisomerase Iloc. Moreover, we and others have previously studied topoisomerase Ila expression in some tumour types (Tuccari et al, 1993; Kaufmann et al, 1994; Holden et al, 1994; Hellemans et al, 1995; Sandri et al, 1996) , and it has been suggested that high levels of protein expression may be associated with histological and cytological features of high grade, poor differentiation or high proliferation (Tuccari et al, 1993; Kaufmann et al, 1994; Hellemans, et al, 1995; Sandri et al, 1996) .
In the present study, expression of topoisomerase Ila was examined both in tumours known to be responsive to topoisomerase IItargeting drugs and in those that display de novo drug resistance. A high level of expression was seen in those tumours known to have a high proliferative index (e.g. seminomas and high-grade non-Hodgkin's lymphomas). While it has been suggested that expression of topoisomerase II isoforms may be responsible for the drug responsiveness of certain tumour types, it is clear that the lack of response to chemotherapy typically seen in colon tumours treated with topoisomerase 11-targeting drugs is not caused by a lack of the target enzyme. Indeed, some of the colon tumours displayed high levels of expression of both topoisomerase IIa and P. This indicates that the inherent drug resistance of colon cancers is probably related to factors other than topoisomerase II expression, such as drug uptake or the ability to induce apoptosis after DNA damage. It would be interesting to analyse the relationship between DNA damage and cell death in these tumours.
Topoisomerase Ila was detected in the cytoplasm of cell lines, normal tissues and tumours. This was seen in both frozen and paraffin-embedded tissue sections. Moreover, we have detected cytoplasmic staining for topoisomerase Ila using a second antibody raised to a different peptide from within the topoisomerase Ila sequence (unpublished observation). This cytoplasmic localization for topoisomerase IIo has not been described previously in human tissues, but a variation in intracellular distribution during the different phases of the cell cycle has been described for topoisomerase II in Drosophila cells (Swedlow et al, 1993) . The role of the cytoplasmic fraction of topoisomerase Ila is not clear at this stage. It is possible that topoisomerase 11o requires phosphorylation for nuclear localization, as has been reported for p53 and several other proteins (reviewed in Jans, 1995) . We, and others, have demonstrated that human topoisomerase Ila is a phosphoprotein and requires phosphorylation for its activation (Kroll and Rowe, 1991; Wells et al, 1994; . The cytoplasmic fraction of topoisomerase Ila protein may act as a reservoir of inactive enzyme that can be simultaneously activated and translocated to the nucleus as and when required. The existence of a cytoplasmic fraction of topoisomerase Ila also implies that the use of Western blotting of whole cell extracts to quantify topoisomerase IIoc protein levels may take into account a fraction of the protein pool that is not localized at its primary site of action and may, therefore, not be functional.
Topoisomerase II has previously been shown to be expressed in quiescent cells in vitro and during all phases of the cell cycle (Woessner et al, 1991) . Consistent with this, we observed positive staining for topoisomerase I13 in virtually all cells in all tissues and tumours. Previous studies using antibodies that recognise a 150-kDa protein, presumed to be a breakdown product of topoisomerase 1I, have suggested that this isoform is localized exclusively to nucleoli (Zini et al, 1992) . Using those antibodies, D'Andrea et al (1994) studied expression of the 150-kDa antigen in melanoma and lung cancer and observed a poor correlation of the expression of this protein with proliferation. In our study, using the 3H10 antibody that exclusively recognizes a 180-kDa protein on Western blots, topoisomerase I1I was found in both nucleoli and the nucleoplasm, in agreement with the findings of Petrov et al (1993) . Indeed, using the 3H10 antibody and a second rabbit polyclonal antibody to topoisomerase II (Houlbrook et al, 1995) , we have not detected a 150-kDa cross-reacting protein on Western blots, and therefore the identity of the previously described 150-kDa protein is not clear at this stage. Because different antibodies may have different affinities for their cognate epitopes and the latter may differ in numbers per molecule, it is not possible to compare directly between topoisomerase 11f3 and topoisomerase Ilo levels by immunohistochemistry.
The widespread expression of topoisomerase I1I in normal, non-proliferating tissues implies that this isoform may undertake an important function in quiescent cells. However, it should be noted that the striking down-regulation of topoisomerase II that has been described in certain drug-resistant cell lines (Osheroff et al, 1991; Pommier, 1993; Beck et al, 1993) possibly indicates that topoisomerase 111 is dispensable for cell division in transformed cell lines in vitro. Our results showing absence of topoisomerase 11I from the nucleus of SUDHL-1 cells during mitosis support this hypothesis. Localization of topoisomerase II in the nucleolus, as well as in the nucleoplasm, could be related to a role in some aspect of ribosomal, as well as general, gene expression. Many of the foci of staining within the nucleoplasm appeared to coincide with the most intense general DNA staining using DAPI (data not shown). Further work will be required to confirm whether or not this co-localization reflects an interaction of topoisomerase II1 with heterochromatin.
In all of the chemoresponsive tumours studied, there was a higher level of expression of topoisomerase II than in normal quiescent tissues. Moreover, the intensity of staining was considerably higher in the tumour tissue than in the proliferating compartment of the normal tissue from which the tumour arose. The proportion of tumour cells expressing topoisomerase II at this elevated level was always greater than the proportion of tumour cells that expressed detectable topoisomerase 1Ia protein, indicating that proliferation alone is unlikely to be the basis of this upregulation of topoisomerase II in many of these tumours. Taken together, these data raise the possibility that the major target for topoisomerase TI-targeting drugs in many human cancers may be topoisomerase 13, and not topoisomerase I1o as has been assumed hitherto. The observation that topoisomerase IP: is frequently upregulated in certain human cancers indicates that this isoform should be evaluated further as a potential target for the development of new anti-tumour agents.
